Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.
Jeter JM, et al. Among authors: meyskens fl jr.
Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3.
Cancer. 2019.
PMID: 30281145
Free PMC article.
Review.